AIROS® Medical, a medical technology manufacturer, recently launched the ARTAIRA® compression device in the United States. The U.S. Food and Drug Administration (FDA) cleared this intermittent pneumatic compression system, enabling at-home therapy that increases blood flow in the lower extremities. This launch represents a significant advancement in non-invasive care for patients with chronic vascular symptoms, such as leg pain and diabetic foot ulcers.
According to the American Limb Preservation Society, global PAD cases are projected to rise by 220 percent by 2050. This increase could affect more than 360 million people worldwide. Consequently, innovative therapies are urgently needed to improve circulation, support wound healing, and reduce the risk of tissue loss or amputation. The ARTAIRA® compression device delivers rapid, high-pressure cycles to the calf, ankle, and foot. That enhances blood flow while improving the patient's quality of life.
Unlike traditional therapies, the ARTAIRA® compression device allows patients to receive treatment at home. This reduces frequent medical visits and hospital stays. With its two-button interface and lightweight design, the device weighs only seven pounds. The large color LCD screen displays real-time pressure and treatment time. Its portability ensures that elderly patients and those with limited mobility can adhere to therapy more consistently.
The global growth of non-communicable diseases, including diabetes, cardiovascular disorders, and respiratory conditions like COPD, creates a strong need for continuous, easily accessible monitoring solutions. This trend highlights the growing demand for home-based testing and therapeutic devices.
Darren M. Behuniak, Chief Operating Officer of AIROS Medical, emphasized that millions of aging Americans suffer from vascular conditions that limit mobility. He explained that ARTAIRA® compression device therapy improves circulation, helping patients resume daily activities. Behuniak added that this device builds on AIROS Medical’s existing product line, which includes treatments for lymphedema and chronic venous insufficiency.
The prescription-only ARTAIRA® compression device uses air compression and tubing to inflate dual-chamber garments worn on the legs. One chamber inflates under the foot, while the other inflates behind the calf. Each chamber reaches 120 mmHg in a timed sequence, simulating the effects of active muscle movement. This repetitive compression supports arterial inflow, reduces pain, promotes ulcer healing, and helps prevent progression to amputation.
The ARTAIRA® compression device is now available throughout the United States with a physician’s prescription. Medicare reimbursement and commercial insurance coverage are possible when proper documentation is provided. To encourage adoption, AIROS Medical is expanding clinical education, offering workshops and live demonstrations at podiatric, vascular, and wound care conferences. These programs aim to educate clinicians, caregivers, and patients about the benefits of intermittent pneumatic compression in PAD management.
Healthcare professionals have welcomed this therapy, especially for patients who are not surgical candidates or require adjunctive treatment after bypass surgery. The ARTAIRA® compression device supports patients and clinicians by combining high performance with simple, at-home usability.
Studies on intermittent pneumatic compression show that rapid, high-pressure sequences significantly improve outcomes for patients with arterial insufficiency. Benefits include enhanced nitric oxide release, which promotes vasodilation and lowers peripheral resistance. The therapy also empties capacitance vessels, improving venous outflow and allowing arterial blood to reach the feet and toes more efficiently.
Patient advocacy groups argue that home-based, non-surgical therapies like ARTAIRA® compression device are crucial given the rising prevalence of PAD. Many patients with intermittent claudication, rest pain, or diabetic foot ulcers experience chronic discomfort and mobility limitations. By providing effective at-home therapy, devices like ARTAIRA® compression device can empower patients to stay active and independent.
In summary, the ARTAIRA® compression device represents an important advancement in PAD care. By delivering advanced, portable intermittent pneumatic compression, AIROS Medical expands treatment options across the United States. As awareness grows among clinicians and patients, this therapy may become central to PAD management, improving circulation, reducing pain, and enhancing overall quality of life.
